Xenios AG
7
1
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
14.3%
1 terminated/withdrawn out of 7 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
50%
1 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS)
Role: lead
Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure
Role: lead
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
Role: lead
Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD
Role: lead
CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases
Role: collaborator
Effects of Blood Pulsatility on Von Willebrand Factor During ECCO2R
Role: collaborator
Synchronized Cardiac Assist for Cardiogenic Shock
Role: lead
All 7 trials loaded